Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

  • Falgàs, Aïda
  • Lázaro-Gorines, Rodrigo
  • Zanetti, Samanta Romina
  • Rubio-Pérez, Laura
  • Martínez-Moreno, Alba
  • Vinyoles, Meritxell
  • Guerrero-Murillo, Mercedes
  • Fernández-Fuentes, Narcís
  • Roca-Ho, Heleia
  • Tirado, Néstor
  • Panisello, Carla
  • Velasco-Hernández, Talia
  • Mayado, Andrea
  • Pérez-Pons, Alba
  • Genescà, Eulàlia
  • Ribera, Josep-Maria
  • Ribera, Jordi
  • Camós, Mireia
  • Ramírez-Orellana, Manuel
  • Anguita, Eduardo
  • Ballerini, Paola
  • Fuster, José Luis
  • Juan, Manel
  • González-Navarro, Azucena
  • Locatelli, Franco
  • Stam, Ronald W.
  • Querol, Sergi
  • Velasco, Pablo
  • Ortiz-Maldonado, Valentín
  • Martínez-Cibrián, Nuria
  • Delgado, Julio
  • Orfao, Alberto
  • Álvarez-Vallina, Luis
  • Bueno, Clara
  • Menéndez, Pablo
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19) T-cell therapy, >50% of patients relapse within a year. Both leukemia cell–intrinsic factors favoring immune escape and poor CAR T-cell persistence contribute to clinical failure. Moreover, the expression of immune checkpoint receptors (ICRs) and their ligands within the bone marrow (BM) microenvironment may contribute to leukemia progression and therapy resistance. Here, we characterized the expression of ICRs and their ligands in leukemic blasts, T cells, and mesenchymal stromal cells (MSCs) from B-ALL BM samples at diagnosis and relapse, comparing them with age-matched healthy BM controls. Our findings reveal a significantly upregulated expression of TIM-3 in T cells and its ligand, galectin-9, in both blasts and MSCs throughout disease progression. The expression of galectin-9 in B-ALL blasts and TIM-3 in CAR19 T cells negatively correlates with clinical outcome. Furthermore, we demonstrate that galectin-9 impairs CAR19 T-cell homeostasis and cytotoxicity. Notably, an engineered TIM-3–Fc decoy receptor, delivered either by primary T cells coadministered with CAR19 T cells or via a bicistronic all-in-one CAR19–TIM-3–Fc construct, improved the antileukemia efficacy and persistence of CAR19 T cells in B-ALL xenograft models. Mechanistically, CAR19–TIM-3–Fc T-cell treatment promotes the in vivo expansion of transduced and bystander effector and memory T cells, as determined by spectral flow cytometry. Collectively, these TIM-3–Fc decoy–armored CAR19 T cells offer a promising therapeutic strategy for patients with R/R B-ALL., Samples included in this study were provided by the collection of samples of the Josep Carreras Leukemia Research Institute (C002922) and were processed following standard operating procedures with the appropriate approval of the Ethics and Scientific Committees. Core support of research in the P.M. laboratory is provided by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa; additional support is provided by the European Research Council (grants ERC-PoC-957466 IT4B-TALL and ERC-PoC-101100665 BiTE-CAR); Horizon 2020 (grant 101057250-CANCERNA), the Ministerio de Economía, Industria y Competitividad (MINECO; grants PID2019-108160RB-I00 and PID2022-142966OB-I00/MCIN/AEI/10.13039/501100011033 and Feder Funds), MINECO/European Union NextGenerationEU (grants CPP2021-008508 and CPP2022-009759); the Spanish Association Against Cancer (AECC; grants PRYGN234975MENE, and PRYGN211192BUEN), the Health Institute Carlos III (ISCIII; grant PI20/00822), the Uno Entre Cien Mil Foundation, Dutch Josep Carreras Leukemia Stifftung (DJCLS; grant 02 R/2023), MINECO (grant PLE2021-007518), and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Research in the L.Á.-V. laboratory is funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/ 501100011033 (grants PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021-121711-100, CPP2022-009762, and CPP2022-009765); the ISCIII/FEDER (grants DTS20/00089 and PMPTA22/00167), the AECC (grants PROYE19084ALVA and PRYGN234844ALVA); the CRIS Cancer Foundation, Spain (grants FCRIS-2021-0090 and FCRIS-2023-0070); the Fundación “La Caixa” (grant HR21-00761 project IL7R_LungCan); the Comunidad de Madrid (grant P2022/BMD-7225 Next Generation CART MAD), and the Fundación d'Estudis i Recerca Oncológica (BBASELGAFERO2024.01). A.F. was supported by a Juan de la Cierva postdoctoral fellowship (FJC2021-046789-I); N.T. was supported by a PhD fellowship (FPU19/00039) from the Spanish Ministry of Science and Innovation; and C.P. was supported by a Contratos predoctorales de formación en investigación en salud fellowship (FI21/00161) from ISCIII. L.R.-P. is supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck. S.R.Z. was supported by a Marie Sklodowska Curie Fellowship (GA 795833)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

  • Arroyo-Ródenas, Javier
  • Falgàs, Aïda
  • Díez-Alonso, Laura
  • Martínez-Moreno, Alba
  • Roca-Ho, Heleia
  • Gil-Etayo, Francisco J.
  • Pérez-Pons, Alba
  • Aguilar-Sopeña, Óscar
  • Velasco-Sidro, Miriam
  • Gómez-Rosel, Marina
  • Jiménez-Matías, Beatriz
  • Muñoz-Sánchez, Guillermo
  • Pacheco, Yedra
  • Bravo-Martín, Clara
  • Ramírez-Fernández, Ángel
  • Jiménez-Reinoso, Anaïs
  • González-Navarro, Azucena
  • Juan, Manel
  • Orfao, Alberto
  • Blanco, Belén
  • Roda-Navarro, Pedro
  • Bueno, Clara
  • Menéndez, Pablo
  • Álvarez-Vallina, Luis
[Background] CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, more than half of patients relapse after CAR-T or TCE therapy, with antigen escape or lineage switching accounting for one-third of disease recurrences. To minimize tumor escape, dual-targeting CAR-T cell therapies simultaneously targeting CD19 and CD22 have been developed and validated both preclinically and clinically., [Methods] We have generated the first dual-targeting strategy for B-cell malignancies based on CD22 CAR-T cells secreting an anti-CD19 TCE antibody (CAR-STAb-T) and conducted a comprehensive preclinical characterization comparing its therapeutic potential in B-ALL with that of previously validated dual-targeting CD19/CD22 tandem CAR cells (TanCAR-T cells) and co-administration of two single-targeting CD19 and CD22 CAR-T cells (pooled CAR-T cells)., [Results] We demonstrate that CAR-STAb-T cells efficiently redirect bystander T cells, resulting in higher cytotoxicity of B-ALL cells than dual-targeting CAR-T cells at limiting effector:target ratios. Furthermore, when antigen loss was replicated in a heterogeneous B-ALL cell model, CAR-STAb T cells induced more potent and effective cytotoxic responses than dual-targeting CAR-T cells in both short- and long-term co-culture assays, reducing the risk of CD19-positive leukemia escape. In vivo, CAR-STAb-T cells also controlled leukemia progression more efficiently than dual-targeting CAR-T cells in patient-derived xenograft mouse models under T cell-limiting conditions., [Conclusions] CD22 CAR-T cells secreting CD19 T-cell engagers show an enhanced control of B-ALL progression compared with CD19/CD22 dual CAR-based therapies, supporting their potential for clinical testing., Research in LA-V laboratory is funded by the MCIN/AEI/10.13039/501100011033 (PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021-121711-I00, CPP2022-009762, CPP2022-009765, CPP2023-010827), the Carlos III (ISCIII) Health Institute with European Regional Development Fund (FEDER) cofinancing (DTS20/00089, PMPTA22/00167); the Asociación Española contra el Cáncer (AECC) (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS-2021-0090 and FCRIS-2023-0070), the Fundación ‘‘La Caixa’’ (HR21-00761 project IL7R_LungCan), the Fundación para la Investigación Biomédica del Hospital 12 de Octubre (programa Investiga 2022-0082), the Comunidad de Madrid (P2022/BMD-7225 Next Generation CART MAD), and the Fundación FERO (BBASELGAFERO2024.01). Research in PM/CB laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support; “the European Research Council grants (ERC-PoC-957466 IT4B-TALL, ERC-PoC-101100665 BiTE-CAR); H2020 (101057250-CANCERNA), the MCIN/AEI/10.13039/501100011033 (PID2022-142966OB-I00 and Feder Funds), MCIN/European Union NextGeneration EU (CPP2021-008508 and CPP2022-009759); the AECC (PRYGN234975MENE and PRYGN211192BUEN), the Fundación Unoentrecienmil (FUECM2024), the ISCIII/FEDER (PI20/00822, PI24/00763) and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). BB is supported by the ISCIII (PI23/01256), AECC (INNOV211832BLAN) and Comunidad de Madrid (IND2022/BMD-23732). PR-N is funded by MCIN/AEI/10.13039/501100011033 (PID2020-115444GB-I00). AF was supported by a Juan de la Cierva fellowship from the Ministerio de Ciencia, Innovación y Universidades. LDA was supported by a Rio Hortega fellowship from the ISCIII (CM20/00004). OA-S was supported by a PhD fellowship from the Complutense University of Madrid. MG-R is supported by an Industrial PhD fellowship from Comunidad de Madrid (IND2022/BMD-23732)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager

  • Gómez-Rosel, Marina
  • Rubio-Pérez, Laura
  • Zagorac, Ivana
  • Domínguez-Alonso, Carmen
  • Díez-Alonso, Laura
  • Hangiu, Oana
  • Navarro, Rocío
  • Torres-Ruiz, Raúl
  • Rodriguez-Perales, Sandra
  • Blanco, Francisco J.
  • Compte, Marta
  • Álvarez-Vallina, Luis
  • Blanco, Belén
22 páginas, 5 figuras, Adoptive therapy with CAR-T cells and systemic administration of bispecific T-cell engagers (TCE) have achieved unprecedented success in the treatment of relapsed/refractory (R/R) B-cell malignancies. However, high relapse rates remain a major challenge. STAb (Secretion of T cell-redirecting bispecific Antibodies)-T-cell immunotherapy represents a promising alternative by enabling both polyclonal T-cell recruitment and sustained bispecific antibody release. Here, we describe an evolution of STAb-T19 therapy, which has demonstrated superior outcomes to those of CAR-T-19 cells in preclinical models of B-ALL, on the basis of the simultaneous secretion of two bispecific antibodies: a CD19 × CD3 TCE and a PD-L1 × 4-1BB bsAb. The combined approach aims to increase the antitumor efficacy of STAb-T19 cells by blocking the PD-1/PD-L1 axis with conditional 4-1BB costimulation to ensure the long-term persistence of STAb-T cells. Preclinical data show that this combination improves cytotoxic activity and prolongs antileukemic efficacy compared with low-dose single STAb-T therapy. Our findings suggest that the integration of PD-L1 × 4-1BB bsAbs into STAb-T19 therapy may maximize efficacy, thereby opening a promising avenue to address resistance and relapse in B-ALL. Moreover, this approach may pave the way for the development of next-generation cell-based therapies for hematologic and solid malignancies., BB is funded by Fundación Científica de la Asociación Española Contra el Cáncer (INNOV211832BLAN), the Comunidad de Madrid (IND2022/BMD−23732) and the Instituto de Salud Carlos III (ISCIII) (PI20/01030, PI23/01256). LA-V is funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 (PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021−121711-I00, CPP2022−009762, CPP2022−009765, CPP2023−010827), ISCIII (DTS20/ 00089, PMPTA22/00167), the Asociación Española contra el Cáncer (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS−2021−0090 and FCRIS−2023−0070), the Fundación ‘‘La Caixa’’ (HR21−00761 project IL7R_LungCan), the Comunidad de Madrid (P2022/BMD−7225 Next Generation CART MAD), and the Fundación FERO (BBASELGAFERO2024.01). M.G.-R. is supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2022/BMD−23732). FJB is funded by PID2023-152271NB-I00 from MCIN/AEI/10.13039/501100011033. We thank the Proteomics service at CIC bioGUNE and the Molecular Interactions service at CIB-CSIC for assisting with the mass spectrometry and SEC-MALS experiments. This study has adhered to ARRIVE guidelines, Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

  • Arroyo Ródenas, Javier
  • Roda Navarro, Pedro
  • Álvarez Vallina, Luis
CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, more than half of patients relapse after CAR-T or TCE therapy, with antigen escape or lineage switching accounting for one-third of disease recurrences. To minimize tumor escape, dual-targeting CAR-T cell therapies simultaneously targeting CD19 and CD22 have been developed and validated both preclinically and clinically.